Chloris Geospatial Raises $8.5 Million Series A to Scale Satellite-Based Forest Carbon Monitoring
With this new funding, Chloris will accelerate product development, grow its commercial and technical teams, and deepen partnerships across corporate carbon accounting for forest risk commodities and the carbon value chain, meeting the market's rising demand for verifiable, high-quality nature-based solutions. The company will also expand its operations with a new European hub to support regional growth and customer engagement.
The investment comes at a pivotal time for the climate and nature agenda, when trust, transparency, and scalable solutions are more urgent than ever.
While the climate and nature crises are global issues, action is taken locally, by governments, project developers, investors, and supply chain actors working across diverse landscapes and regions. Aligning local actions with global ambition demands fit-for-purpose solutions that are both scientifically rigorous and operationally scalable at every level.
Chloris' technology responds directly to this need, enabling better decisions through transparent, science-based insights.
Developed under the guidance of Co-Founder and Chief Science Officer Dr. Alessandro Baccini , the Chloris technology uses satellite data, proprietary sensor fusion and machine learning to measure vegetation, going far beyond traditional land cover mapping. Chloris is uniquely positioned to provide high-quality, affordable, and timely data on what has happened in every acre of forest around the world since the year 2000.
"This is a decisive moment," said Marco Albani , CEO and Co-Founder of Chloris. "To protect and restore nature at the pace and scale the climate demands, we need tools that make it easy to act—with confidence. That's what Chloris enables, and this investment allows us to take it to the next level. We're thrilled by the support of Future Energy Ventures and honored by the continued belief in our mission from all of our investors."
As science has been telling us, forests are essential carbon sinks, biodiversity havens, and socio-economic assets—and the urgency to protect and restore them has never been greater. In the past year alone, record-breaking wildfires and declining biomass trends, visible in Chloris data, have highlighted the accelerating loss of forest carbon. Reversing this trend requires scaling investment in nature, but doing so depends on our ability to accurately quantify biomass dynamics with confidence and consistency.
"We invested in Chloris Geospatial because we believe their technology is the missing link to restoring trust and unlocking growth in carbon markets, as well as improving accounting standards. The ability to independently, transparently, and affordably measure carbon dynamics across all woody vegetation globally represents a step change in how we monitor and account for nature-based climate solutions," said Patrick Elftmann , Managing Partner at Future Energy Ventures.
Across both voluntary carbon markets and corporate supply chains, organizations are increasingly relying on satellite-based insights to assess, invest in, and monitor forest carbon projects and to report emissions and removals in alignment with protocols like the GHG Protocol.
"At AXA IM Alts, investing in solutions that protect, restore, and sustainably manage natural capital is core to our mission. Our continuous support for Chloris reflects our belief that scalable, science-based measurement is critical to driving integrity and impact in both carbon markets and corporate climate strategies," said Adam Gibbon , Natural Capital Lead at AXA IM Alts.
Chloris' clients include leading corporations working to monitor forest-risk supply chains and make data-driven decisions aligned with climate goals and carbon accounting standards, forward-looking developers of nature-based solutions, and innovative carbon markets standards. Organizations rely on Chloris' analysis to quantify forest carbon dynamics with confidence and integrate transparent, science-based data into their climate reporting.
About Chloris Geospatial
Chloris Geospatial is a leading provider of science-based forest carbon insights, combining AI, machine learning, and satellite technology to deliver high-integrity carbon data at scale. Chloris empowers businesses, governments, and project developers to make informed decisions with consistent, cost-effective, and verifiable data, maximizing impact on the ground.
For more information, visit: www.chloris.earth
About Future Energy Ventures
Future Energy Ventures (FEV) is one of the leading platforms for early-stage climate tech startups and scaleups globally. Fund II, an SFDR Article 9 fund, invests in digital and digitally enabled climate technologies with high potential to redefine the energy world and build cleaner, smarter cities. Founded in 2016, FEV partners with exceptional founders and offers opportunities for financing, cooperation, and scaling through industry and investor partners.
SOURCE Chloris Geospatial
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
21 minutes ago
- CTV News
CTV National News: How Trump is justifying a tariff on imported copper
Watch Donald Trump says a 50 per cent tariff on imported copper will come into effect as of Aug. 1, citing national security concerns. Mike Le Couteur has more.
CTV News
an hour ago
- CTV News
Windsor metal shop owner bracing for possible Trump tariff on copper exports
At RJ Steel Co., Ryan Jordan and his staff shifted focus to copper to avoid steel tariffs. Now that metal faces a potential tariff of its own. (Travis Fortnum/CTV News Windsor) Just minutes from the U.S. border, a Windsor metal fabricator says he's anxiously watching trade developments that could hit his bottom line. Ryan Jordan, owner of RJ Steel Co., ships fabricated copper, steel and aluminum products across the border — with about 15 to 20 per cent of his revenue tied to U.S. clients. 'I spoke with one customer today who says, 'What's this mean about your price now? Is this price that you've provided us a month ago — does that still stand?' And I said, I do not know. I do not know at this point,' said Jordan. In 2018, when President Donald Trump first imposed tariffs on imported steel and aluminum, Jordan pivoted his operations — investing more in copper fabrication, which wasn't targeted at the time. 'It was a good fit for us,' he said. 'It allowed us to put money towards something that wouldn't affect us with the tariffs. And copper was not tariffed at the time.' Now, it could be. Trump, who is in office again, announced this week that he plans to impose a 50 per cent tariff on imported copper. Wednesday evening he said that would be in place August 1. 'I'm as nervous as I was in 2018,' said Jordan. Industry Minister Melanie Joly addressed the matter Wednesday morning, saying no formal order had yet been issued. 'When it comes to the latest declaration from the President in the United States, we have not yet seen an executive order,' she said. Canada exported $9.3 billion worth of copper in 2023 — with 52 per cent of that going to the U.S. Joly said the federal government's priority is protecting Canadian jobs and businesses from what she called 'unjustifiable and unjustified tariffs.' 'My job right now is to make sure that in the context of this trade war, I'm supporting the front lines of this trade war, which are the workers and the companies affected,' she said. Jordan said the uncertainty alone could put local businesses like his at a disadvantage. 'In a competitive atmosphere or a competitive market, you're going to find that every dollar counts,' he said.
National Post
an hour ago
- National Post
Canadian pharmaceutical industry alarmed after Trump threatens 200% tariff on drug imports
WASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril. Article content 'Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals,' said Canadian Generic Pharmaceutical Association president Jim Keon. Article content Article content On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties. Article content Article content Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India. Article content A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month. Article content Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the U.S., Keon said. Article content Such a low volume shouldn't trigger any U.S. concerns about an overreliance on imports, Keon said. Article content He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal. Article content Article content 'We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves,' Keon said. Article content Article content But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country. Article content Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market. Article content 'I think as a Canadian industry and as part of a global industry, we've been operating without tariffs for the last several decades and imposing tariffs is going to increase costs and complicate supply chains,' Keon said.
